Ann: RARE GENETIC CANNABIS DISCOVERY, page-2

The Board of Queensland Bauxite Limited (ASX: QBL) is pleased to announce the next phase in Medical Cannabis Limited’s (MCL) research and cultivation project. This project has just received approval to commence the transfer of plants grown indoors to its Tabulam Cannabis Project (TCP). Currently it is our understanding that MCL is the only company in Australia who has approval to transfer its indoor plants to be grown externally.

Andrew Kavasilas, MCL’s Technical Director said: “We just can’t wait to get those plants into the ground so we get a better idea of their full agronomic potential. We’re also thrilled that we have already begun to identify a very rare and unique characteristic in a particular Cannabis plant.”

MCL is delighted to announce the discovery of a ‘Triploid’ in the midst of a research program (See photos below). A ‘triploid’ plant produces an extra branch where there should be just two. In effect, the plant produces an extra 50% more branches and biomass. This is a rare mutation and the genetics will be of great value if successfully bred into commercial crops.

“Things are certainly moving much faster than we had anticipated. When we have our trial plots planted out with the selected seedlings that were propagated indoors, we will follow this up with broad acre cultivation of winter hemp crops from which we will be ready to harvest the seeds, and will be able to coincide with the anticipated full legalisation of hemp seed food consumption in Australia.”

MCL is at the forefront of Australian companies to approach this early type of research in such a thorough manner and finds itself amongst world class investigators in a brave new world of Cannabis genetic identification.